Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Foghorn Therapeutics Inc.

    NASDAQ: FHTX · Real-Time Price · USD
    4.14
    -0.06 (-1.43%)
    At close: Jun 05, 2025, 3:59 PM
    3.96
    -4.35%
    After-hours: Jun 05, 2025, 04:54 PM EDT

    Foghorn Therapeutics Statistics

    Share Statistics

    Foghorn Therapeutics has 55.74M shares outstanding. The number of shares has increased by 0.51% in one year.

    Shares Outstanding

    n/a
    		 55.74M

    Shares Change (YoY)

    n/a
    		 0.51%

    Shares Change (QoQ)

    n/a
    		 0.03%

    Owned by Institutions (%)

    n/a
    		 64.28%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 6,505

    FTD / Avg. Volume

    n/a
    		 5.22%

    Short Selling Information

    The latest short interest is 1.07M, so 1.92% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.07M

    Short % of Shares Out

    n/a
    		 1.92%

    Short % of Float

    n/a
    		 2.92%

    Short Ratio (days to cover)

    n/a
    		 8.74

    Valuation Ratios

    The PE ratio is -2.99 and the forward PE ratio is -3.33. Foghorn Therapeutics's PEG ratio is 0.09.

    PE Ratio

    n/a
    		 -2.99

    Forward PE

    n/a
    		 -3.33

    PS Ratio

    n/a
    		 11.46

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 -5.69

    P/FCF Ratio

    n/a
    		 -2.56

    PEG Ratio

    n/a
    		 0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Foghorn Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.73, with a Debt / Equity ratio of -0.82.

    Current Ratio

    n/a
    		 3.73

    Quick Ratio

    n/a
    		 3.73

    Debt / Equity

    n/a
    		 -0.82

    Debt / EBITDA

    n/a
    		 -0.38

    Debt / FCF

    n/a
    		 -0.37

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $201,803.57

    Profits Per Employee

    n/a
    		 $-773,392.86

    Employee Count

    n/a
    		 112

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -33.55% in the last 52 weeks. The beta is 3.05, so Foghorn Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 3.05

    52-Week Price Change

    n/a
    		 -33.55%

    50-Day Moving Average

    n/a
    		 3.98

    200-Day Moving Average

    n/a
    		 5.93

    Relative Strength Index (RSI)

    n/a
    		 48.67

    Average Volume (20 Days)

    n/a
    		 124,504

    Income Statement

    In the last 12 months, Foghorn Therapeutics had revenue of 22.6M and earned -86.62M in profits. Earnings per share was -1.58.

    Revenue

    n/a
    		 22.6M

    Gross Profit

    n/a
    		 22.6M

    Operating Income

    n/a
    		 -102.68M

    Net Income

    n/a
    		 -86.62M

    EBITDA

    n/a
    		 -97.17M

    EBIT

    n/a
    		 -100.28M

    Earnings Per Share (EPS)

    n/a
    		 -1.58
    Full Income Statement

    Balance Sheet

    The company has 55.45M in cash and 37.13M in debt, giving a net cash position of 18.32M.

    Cash & Cash Equivalents

    n/a
    		 55.45M

    Total Debt

    n/a
    		 37.13M

    Net Cash

    n/a
    		 18.32M

    Retained Earnings

    n/a
    		 -558.18M

    Total Assets

    n/a
    		 258.69M

    Working Capital

    n/a
    		 154.11M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -100.41M and capital expenditures -906K, giving a free cash flow of -101.31M.

    Operating Cash Flow

    n/a
    		 -100.41M

    Capital Expenditures

    n/a
    		 -906K

    Free Cash Flow

    n/a
    		 -101.31M

    FCF Per Share

    n/a
    		 -1.85
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -454.31% and -383.24%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -454.31%

    Pretax Margin

    n/a
    		 -383.24%

    Profit Margin

    n/a
    		 -383.24%

    EBITDA Margin

    n/a
    		 -429.9%

    EBIT Margin

    n/a
    		 -454.31%

    FCF Margin

    n/a
    		 -448.24%

    Dividends & Yields

    FHTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for FHTX is $11.5, which is 177.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11.5

    Price Target Difference

    n/a
    		 177.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -3.08

    Piotroski F-Score

    n/a
    		 0

    Add to Watchlist